TGen's Dr. Daniel D. Von Hoff among first selected for Fellows of the AACR Academy

American Association for Cancer Research honors distinguished cancer scientists

PHILADELPHIA - March 25, 2013 - Dr. Daniel D. Von Hoff, Physician-In-Chief of the Translational Genomics Research Institute (TGen), is among the first class selected by the American Association for Cancer Research for its newly formed Fellows of the AACR Academy.

Dr. Von Hoff will be among those inaugurated to the Fellows of the AACR Academy at the AACR Annual Meeting 2013, April 6-10 in Washington, D.C.

The AACR Academy has been created to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. These Fellows have been selected through a rigorous peer review process that evaluates individuals on the basis of their stellar scientific achievements in cancer research.

"Our Board of Directors made the decision to establish the AACR Academy as a mechanism for recognizing scientists whose contributions to the cancer field have had an extraordinary impact. Membership in the Fellows of the AACR Academy will be the most prestigious honor bestowed by the American Association for Cancer Research," said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR.

The Fellows of the AACR Academy is as a separate entity within the American Association for Cancer Research, and only individuals who have made exceptional contributions to cancer and/or cancer-related biomedical science are eligible for election.

The inaugural class of Fellows will be inducted into the AACR Academy on Friday, April 5, 2013, at the National Museum of Women in the Arts in Washington, D.C. at 6:30 p.m. Reporters who wish to attend this dinner must RSVP to Jeremy Moore, associate director of media relations at AACR, at [email protected] no later than March 28.

The induction ceremony will be followed by a meeting of the Academy on Saturday, April 6, and special recognition of the inaugural Fellows during the opening plenary session on Sunday, April 7, 2013. These events will be annual occurrences at future AACR Annual Meetings.

The inaugural class of Fellows of the AACR Academy will consist of 106 individuals, symbolizing the age of the organization upon establishment of the Academy.

Future classes of Fellows shall consist of no more than 11 individuals, in honor of the 11 founding members of the American Association for Cancer Research. These Fellows will be elected by vote of all the Fellows of the AACR Academy.

The inaugural Fellows of the AACR Academy are:

  • Karen H. Antman, M.D., Provost, Boston University Medical Campus; Dean, School of Medicine at Boston University
  • David Baltimore, Ph.D., Robert Andrews Millikan Professor of Biology, President Emeritus at California Institute of Technology
  • Françoise Barré-Sinoussi, Ph.D., Professor and Director, Regulation of Retroviral Infections Unit, Virology Department at the Institut Pasteur
  • Paul Berg, Ph.D., Director Emeritus, Department of Biochemistry at Stanford University School of Medicine
  • Joseph R. Bertino, M.D. Chief Scientific Officer; Co-Leader, Cancer Pharmacology and Preclinical Therapeutics Research Program at The Cancer Institute of New Jersey; and University Professor of Medicine and Pharmacology at UMNDJ-Robert Wood Johnson Medical School
  • J. Michael Bishop, M.D., Professor and Director, The G.W. Hooper Foundation at UCSF
  • Mina J. Bissell, Ph.D., Distinguished Scientist and Director, Life Sciences Division at Lawrence Berkeley National Laboratory
  • Elizabeth H. Blackburn, Ph.D., Morris Herzstein Endowed Chair in Biology & Physiology; Professor, Departments of Biochemistry/Biophysics and Microbiology/Immunology at UCSF
  • Sydney Brenner, MB.BCh., D. Phil., Founder, Acidophil, LLC; Distinguished Professor, Salk Institute
  • Angela H. Brodie, Ph.D., Professor of Pharmacology, University of Maryland School of Medicine, and Investigator, University of Maryland Marlene and Stewart Greenebaum Cancer Center
  • Mario R. Capecchi, Ph.D., Distinguished Professor of Human Genetics at the University of Utah
  • Webster K. Cavenee, Ph.D., Director, Ludwig Institute for Cancer Research San Diego; Distinguished Professor, University of California at San Diego
  • Martin Chalfie, Ph.D., William R. Kenan, Jr. Professor of Biological Sciences; Chair, Department of Biological Sciences at Columbia University
  • Zhu Chen, Ph.D., Minister of Health at the Ministry of Health of the People's Republic of China
  • Aaron J. Ciechanover, M.D., D.Sc., Distinguished Research Professor at Technion-Israel Institute of Technology
  • Bayard D. Clarkson, M.D., Member and Head, Laboratory of Hematopoietic Cell Kinetics at Memorial Sloan-Kettering Cancer Center
  • Donald S. Coffey, Ph.D., Catherine Iola and J. Smith Michael Distinguished Professor of Urology at Johns Hopkins University School of Medicine
  • Stanley N. Cohen, M.D., Kwoh-Ting Li Professor of Genetics and Professor of Medicine at Stanford University School of Medicine
  • Suzanne Cory, Ph.D., Research Professor, Molecular Genetics of Cancer Division; Vice-Chancellor's Fellow Walter & Eliza Hall Institute of Medical Research; The University of Melbourne
  • Carlo M. Croce, M.D., Professor and Chair, Department of Molecular Virology, Immunology and Medical Genetics at The Ohio State University Comprehensive Cancer Center
  • Tom Curran, Ph.D., Deputy Scientific Director, Division of Cancer Pathobiology Children's Hospital of Philadelphia Research Institute
  • Brian J. Druker, M.D., Director, JELD-WEN; Chair of Leukemia Research and Investigator at OHSU Knight Cancer Institute; Oregon Health & Science University; Howard Hughes Medical Institute
  • Raymond N. DuBois, M.D., Ph.D., Executive Director, Biodesign Institute at Arizona State University
  • Sir Martin J. Evans, Ph.D., Chancellor at Cardiff University
  • Emmanuel Farber, M.D., Ph.D., Professor Emeritus, Department of Pathology at the University of Toronto
  • Napoleone Ferrara, M.D., Ph.D., Distinguished Professor, University of California,
    San Diego
  • Isaiah J. Fidler, D.V.M., Ph.D., Head, Metastasis Research Laboratory and R. E. "Bob" Smith Distinguished Chair in Cell Biology, Department of Cancer Biology at the University of Texas MD Anderson Cancer Center
  • Bernard Fisher, M.D., Distinguished Service Professor, Surgery at the University of Pittsburgh
  • Joseph F. Fraumeni Jr., M.D., Senior Investigator and Advisor to National Cancer Institute Division of Cancer Epidemiology & Genetics, Office of the Director
  • Emil Frei III, M.D., Director and Physician-in-Chief Emeritus; Richard and Susan Smith Distinguished Professor of Medicine, at Dana-Farber Cancer Institute
  • Elaine V. Fuchs, Ph.D., Investigator, Laboratory of Mammalian Cell Biology & Development at the Howard Hughes Medical Institute at Rockefeller University
  • Judy E. Garber, M.D., M.P.H., Director, Center for Cancer Genetics and Prevention at the Dana-Farber Cancer Institute
  • Walter Gilbert, Ph.D., Vice Chairman and Co-Founder at Paratek Pharmaceuticals, Inc.
  • Alfred G. Gilman, M.D., Ph.D., Professor Emeritus, Department of Pharmacology at the University of Texas Southwestern Medical Center
  • Carol W. Greider, Ph.D., Director and Professor, Molecular Biology & Genetics at Johns Hopkins University School of Medicine
  • Roger C.L. Guillemin, M.D., Ph.D., Distinguished Professor at the Salk Institute for Biological Studies
  • Sir John B. Gurdon, D.Phil., Distinguished Group Leader at The Wellcome Trust/Cancer Research UK Gurdon Institute
  • William N. Hait, M.D., Ph.D., Global Head at Janssen Research & Development, LLC, and Clinical Professor of Medicine, UMDNJ-Robert Wood Johnson Medical School
  • Leland H. Hartwell, Ph.D., President & Director Emeritus, Center for Sustainable Health Biodesign Institute at Arizona State University
  • Avram Hershko, M.D., Ph.D., Distinguished Professor, Unit of Biochemistry Technion-Israel Institute of Technology
  • James F. Holland, M.D., Distinguished Professor of Neoplastic Disorders at the Icahn School of Medicine at Mount Sinai
  • Jimmie C. Holland, M.D., Wayne E. Chapman Chair in Psychiatric Oncology; Attending Psychiatrist, Department of Psychiatry and Behavioral Sciences at Memorial Sloan-Kettering Cancer Center
  • Waun Ki Hong, M.D., Professor and Head, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center
  • Leroy E. Hood, M.D., Ph.D., President and Co-Founder of the Institute for Systems Biology
  • H. Robert Horvitz, Ph.D., David H. Koch Professor of Biology at the Massachusetts Institute of Technology
  • Susan Band Horwitz, Ph.D., Distinguished Professor and Co-Chair, Department of Molecular Pharmacology at the Albert Einstein College of Medicine of Yeshiva University
  • Sir R. Timothy Hunt, Ph.D., Emeritus Group Leader, ICRF Clare Hall Laboratories at Cancer Research UK
  • Tony Hunter, Ph.D., Professor, Hunter Lab (MCBL-H) at the Salk Institute for Biological Studies
  • Tyler Jacks, Ph.D., Director of the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology
  • Peter A. Jones, Ph.D., D.Sc., Distinguished Professor of Urology, Biochemistry and Molecular Biology at USC Norris Comprehensive Cancer Center
  • V. Craig Jordan, Ph.D., D.Sc., Vice Chairman, Department of Oncology Georgetown Lombardi Comprehensive Cancer Center
  • Yuet Wai Kan, M.D., Louis K. Diamond Professor of Hematology at UCSF
  • Mary-Claire King, Ph.D., Professor, Division of Medical Genetics at the University of Washington School of Medicine
  • Eva Klein, M.D., Ph.D., Professor Emeritus, Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet
  • George Klein, M.D., Ph.D., Professor Emeritus, Tumour Biology at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet
  • Alfred G. Knudson Jr., M.D., Ph.D., Distinguished Scientist and Senior Advisor to the President at Fox Chase Cancer Center
  • Brian K. Kobilka, M.D., Professor, Molecular and Cellular Physiology at Stanford University School of Medicine
  • Margaret L. Kripke, Ph.D., Vivian L. Smith Distinguished Chair and Professor in Immunology Emerita at the University of Texas MD Anderson Cancer Center
  • Philip Leder, M.D., Professor Emeritus, Department of Genetics at Harvard Medical School
  • Robert J. Lefkowitz, M.D., James B. Duke Professor of Medicine, HHMI at Duke University Medical Center
  • Arnold J. Levine, Ph.D., Professor, Systems Biology at the Institute for Advanced Study
  • Lawrence A. Loeb, M.D., Ph.D., Professor, Department of Pathology at the University of Washington
  • Tak W. Mak, Ph.D., Director, Advanced Medical Discovery Institute; Director, The Campbell Family Institute for Breast Cancer Research; Senior Scientist, Division of Stem Cell and Developmental Biology, Advanced Medical Discovery Institute/Ontario Cancer Institute at the Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute
  • Lynn M. Matrisian, Ph.D., Vice President, Scientific and Medical Affairs at the Pancreatic Cancer Action Network
  • Frank McCormick, Ph.D., Director at the UCSF Helen Diller Family Comprehensive Cancer Center
  • John Mendelsohn, M.D., Director, IPCT at the University of Texas MD Anderson Cancer Center
  • Donald Metcalf, M.D., Professor Emeritus at the University of Melbourne
  • Enrico Mihich, M.D., Presidential Scholar and Special Assistant to the President for Sponsored Research at the Dana-Farber Cancer Institute
  • Beatrice Mintz, Ph.D., Professor and Jack Schultz Chair in Basic Research at Fox Chase Cancer Center
  • Luc Montagnier, M.D., Professor of Biology and Medicine at Shanghai Jiao Tong University
  • Harold L. Moses, M.D., Hortense B. Ingram Professor of Molecular Oncology; Professor and Acting Chair of Cancer Biology; Professor of Medicine and Pathology, Microbiology and Immunology; Director Emeritus at Vanderbilt-Ingram Comprehensive Cancer Center
  • Sir Paul M. Nurse, Ph.D., President Emeritus; Professor, Laboratory of Yeast Genetics and Cell Biology at The Rockefeller University
  • Olufunmilayo I. Olopade, M.D., Walter L. Palmer Distinguished Service Professor at the University of Chicago Medical Center
  • Arthur B. Pardee, Ph.D., Professor, Department of Biological Chemistry and Molecular Pharmacology at Dana-Farber Cancer Institute and Harvard Medical School
  • Martine J. Piccart, M.D., Ph.D., Head, Medicine Department at the Institut Jules Bordet
  • Sir Bruce A.J. Ponder, Ph.D., Director at Cancer Research UK Cambridge Research Institute
  • Sir Richard J. Roberts, Ph.D., Chief Scientific Officer at New England Biolabs, Inc.
  • Irwin A. Rose, Ph.D., Distinguished Professor-Emeritus, Department of Physiology & Biophysics at the University of California at Irvine
  • Janet D. Rowley, M.D., Blum-Riese Distinguished Professor of Medicine at the University of Chicago Medical Center
  • Frederick Sanger, Ph.D., Medical Research Council Laboratory of Molecular Biology
  • Alan C. Sartorelli, Ph.D., Alfred Gilman Professor of Pharmacology at Yale University School of Medicine; Department of Pharmacology
  • Andrew V. Schally, PhD., Distinguished Medical Research Scientist, Research at the University of Miami VA Medical Center
  • Phillip A. Sharp, Ph.D., Institute Professor at the MIT Koch Institute for Integrative Cancer Research
  • Charles J. Sherr, M.D., Ph.D., Investigator HHMI, Chairman of Tumor Cell Biology at St. Jude Children's Research Hospital
  • Osamu Shimomura, Ph.D., Professor Emeritus at Boston University School of Medicine
  • Dennis J. Slamon, M.D., Ph.D., Director, Clinical/Translational Research; Director, Revlon/UCLA Women's Cancer Research Program, Jonsson Comprehensive Cancer Center; Professor of medicine; Chief of the Division of Hematology/Oncology; Executive Vice Chair for Research, Department of Medicine, University of California, Los Angeles
  • Oliver Smithies, D. Phil., Weatherspoon Eminent Distinguished Professor at the University of North Carolina at Chapel Hill
  • Michael B. Sporn, M.D., Professor of Pharmacology & Medicine at Dartmouth Medical School
  • Louise C. Strong, M.D., Professor, Department of Genetics at the University of Texas MD Anderson Cancer Center
  • Takashi Sugimura, M.D., Ph.D., Vice President at The Japan Academy
  • Sir John E. Sulston, Ph.D., Professor and Chair of the Institute for Science, Ethics and Innovation at the University of Manchester
  • Jack W. Szostak, Ph.D., Investigator, Howard Hughes Medical Institute, Massachusetts General Hospital
  • Roger Y. Tsien, Ph.D., Professor of Pharmacology and of Chemistry & Biochemistry, the University of California, San Diego
  • Arthur C. Upton, M.D., Clinical Professor of Environmental and Occupational Medicine, UMDNJ-Robert Wood Johnson Medical School
  • George F. Vande Woude, Ph.D., Distinguished Scientific Fellow at Van Andel Research Institute
  • Bert Vogelstein, M.D., Professor of Oncology and Pathology, Investigator, Howard Hughes Medical Institute at Johns Hopkins Kimmel Comprehensive Cancer Center
  • Peter K. Vogt, Ph.D., Executive VP and CSO, The Scripps Research Institute
  • Daniel D. Von Hoff, M.D., Physician-in-Chief, Clinical Research at the Translational Genomics Research Institute (TGen).
  • Geoffrey M. Wahl, Ph.D., Professor, Gene Expression Laboratory at the The Salk Institute
  • James D. Watson, Ph.D., Chancellor Emeritus at the Cold Spring Harbor Laboratory
  • Lee W. Wattenberg, M.D., Professor of Laboratory Medicine & Pathology at the University of Minnesota
  • Robert A. Weinberg, Ph.D., Founding Member, Professor of Biology at the MIT Whitehead Institute for Biomedical Research
  • John H. Weisburger, Ph.D., Consultant at Weisburger Associates
  • Jane Cooke Wright, M.D., Deceased.
  • Shinya Yamanaka, M.D., Ph.D., Senior Investigator and the L.K. Whittier Foundation Investigator in Stem Cell Biology at the Gladstone Institutes; Professor of Anatomy, UCSF; Director, Center for iPS Cell Research and Application (CiRA), Kyoto University; Principal Investigator at the Institute for Integrated Cell-Material Sciences, Kyoto University
  • Harald zur Hausen, M.D., Professor Emeritus at the German Cancer Research Center

# # #

Follow the AACR on Twitter: @aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org

About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.

Media Contact:
Jeremy Moore
(215) 446-7109
[email protected]

*

About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]


Search



Media Contact



RSS Feed

Newsletter